In this scenario, an increase in acute circulatory FABP3 may be beneficial, for example, after acute myocardial infarction; however, a chronic presence of circulatory FABP3 in PAD patients may be beneficial for similar reasons but is countered by the detrimental additive effect to increase the severity of PAD. The gene discussed is FABP3; the disease is myocardial infarction.